Treatment Action Group (TAG) released the first TB chapter of its 2023 Pipeline Report offering a contextualized overview of TB vaccine candidates currently in clinical development. Tuberculosis Vaccines by Mike Frick is now available online as a downloadable PDF.
We cannot end TB without new and effective vaccines. Hearteningly, much progress has been made to that end: the pipeline is more robust than it ever has been, with tens of thousands of participants being recruited into Phase III trials across the globe. In 2023, some $600 million was pledged toward TB vaccine research, including $550 million from the Bill and Melinda Gates Foundation and the Wellcome Trust for a long-awaited Phase III trial of M72/AS01E slated to start in 2024. These commitments dwarf the woefully inadequate $143 million spent on TB vaccine R&D in 2022. Read more here.
Comments